<p>摩根大通降低了其在 Amphastar Pharmaceuticals, Inc.（NASDAQ:AMPH - 免费报告）股票中的持股比例，第四季度持股下降了 71.5%，根据其最近向证券交易委员会提交的 13F 表格。该机构投资者在本季度出售了 385,349 股后，持有 153,571 股该公司的股票。截至最近报告期末，摩根大通持有的 Amphastar Pharmaceuticals 的股份约占 0.32%，价值 5,702,000 美元。</p>
<ul>
<li>在降息前值得购买的前两只小型医疗股</li>
</ul>
<p>其他几家机构投资者和对冲基金最近也增加或减少了对 AMPH 的持股。Pacer Advisors Inc.在第四季度将其在 Amphastar Pharmaceuticals 的持股比例提高了 51,977.4%。Pacer Advisors Inc.现在持有 1,350,368 股该公司的股票，价值 50,139,000 美元，此前在上个季度又购买了 1,347,775 股。Boston Trust Walden Corp 在第四季度将其在 Amphastar Pharmaceuticals 的持股比例提高了 81.4%。Boston Trust Walden Corp 现在持有 978,920 股该公司的股票，价值 36,347,000 美元，此前在上个季度又购买了 439,281 股。Boston Partners 在第四季度购买了价值约 15,778,000 美元的 Amphastar Pharmaceuticals 新股份。Wealthfront Advisers LLC 在第四季度购买了价值 9,268,000 美元的 Amphastar Pharmaceuticals 新股份。最后，Raymond James Financial Inc.在第四季度购买了价值 3,450,000 美元的 Amphastar Pharmaceuticals 新股份。机构投资者持有该公司 65.09% 的股票。</p>
<h2>Amphastar Pharmaceuticals 的内部买卖</h2>
<p>在相关消息中，首席财务官 William J. Peters 于 3 月 4 日星期二出售了 4,231 股 Amphastar Pharmaceuticals 的股票。该股票以 27.54 美元的平均价格出售，总价值为 116,521.74 美元。交易完成后，首席财务官现在直接持有 97,363 股该公司的股票，价值约为 2,681,377.02 美元。这笔交易代表了他们持有股票的比例减少了 4.16%。该交易已在向 SEC 提交的文件中披露，相关文件可通过此链接访问。27.10% 的股票由内部人士持有。</p>
<h2>分析师设定新目标价</h2>
<ul>
<li>有前景的小型生物技术公司 Amphastar 经历了可操作的回调</li>
</ul>
<p>几位研究分析师最近对 AMPH 股票发表了看法。Piper Sandler 将 Amphastar Pharmaceuticals 的目标价从 36.00 美元下调至 32.00 美元，并在 3 月 21 日的研究报告中对该股票给予了 “中性” 评级。Needham &amp; Company LLC 在 4 月 10 日的研究报告中重申了对 Amphastar Pharmaceuticals 股票的 “持有” 评级。</p>
<p><strong>阅读我们最新的 AMPH 股票分析</strong></p>
<h2>Amphastar Pharmaceuticals 股票上涨 1.6%</h2>
<p>AMPH 的股票在周五开盘价为 23.35 美元。该股票的 50 日移动平均价格为 27.78 美元，200 日移动平均价格为 37.36 美元。Amphastar Pharmaceuticals, Inc.的 52 周最低价为 22.64 美元，最高价为 53.96 美元。该公司的市值为 11.1 亿美元，市盈率为 7.78，PEG 比率为 2.19，贝塔值为 0.79。该公司的速动比率为 2.61，流动比率为 3.43，债务与股本比率为 0.82。</p>
<h2>Amphastar Pharmaceuticals 公司简介</h2>
<p>（免费报告）</p>
<p>Amphastar Pharmaceuticals, Inc.是一家生物制药公司，在美国、中国和法国开发、生产、营销和销售仿制药和专有的注射、吸入和鼻用产品。它提供 BAQSIMI，一种用于治疗严重低血糖的鼻用喷雾剂；Primatene Mist，一种用于暂时缓解间歇性哮喘轻微症状的非处方肾上腺素吸入产品；Enoxaparin，用于预防和治疗深静脉血栓；REXTOVY 和 Naloxone 用于阿片类药物过量；用于紧急情况的胰高血糖素注射套件；以及 Cortrosyn，用作筛查肾上腺皮质功能不全患者的诊断剂。</p>
<h2>精选文章</h2>
<ul>
<li>我们更看好的五只股票超过 Amphastar Pharmaceuticals</li>
<li>什么是股息？购买最佳股息股票</li>
<li>3 只中型到大型股票宣布了重大回购</li>
<li>什么是道琼斯狗策略？概述和示例</li>
<li>这 3 只股票在过去 12 个月中为股东带来了巨大的收益</li>
<li>成长股：它们是什么，示例及如何投资</li>
<li>知名对冲基金收购 HPE 的巨大股份：现在值得购买吗？</li>
</ul>
<p><strong>想看看其他对冲基金持有的 AMPH 吗？</strong> 访问 HoldingsChannel.com 获取 Amphastar Pharmaceuticals, Inc.（NASDAQ:AMPH - 免费报告）的最新 13F 文件和内部交易。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QU1QSA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QU1QSA"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对本故事有任何问题或意见，请发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Amphastar Pharmaceuticals 吗？</h2>
<p>在考虑投资 Amphastar Pharmaceuticals 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐，现在就购买，以便在更广泛的市场注意到之前……而 Amphastar Pharmaceuticals 并不在名单上。</p>
<p>虽然 Amphastar Pharmaceuticals 目前在分析师中获得 “持有” 评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

摩根大通

Amphastar制药

<p>摩根大通已将其在 Amphastar Pharmaceuticals, Inc.（纳斯达克代码：AMPH）的持股减少了 71.5%，在第四季度出售了 385,349 股，剩余持有 153,571 股，价值约为 570 万美元。其他机构投资者也调整了他们的持股，Pacer Advisors Inc.显著增加了其持股。该股票开盘价为 23.35 美元，52 周区间为 22.64 美元至 53.96 美元。分析师们设定了新的价格目标，Piper Sandler 将其目标从 36.00 美元下调至 32.00 美元，并维持 “中性” 评级</p>

<p>JPMorgan Chase &amp; Co. lowered its holdings in shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH - Free Report) by 71.5% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 153,571 shares of the company's stock after selling 385,349 shares during the quarter. JPMorgan Chase &amp; Co. owned approximately 0.32% of Amphastar Pharmaceuticals worth $5,702,000 at the end of the most recent reporting period.</p>
<div class="lb-trans"><p>摩根大通降低了其在 Amphastar Pharmaceuticals, Inc.（NASDAQ:AMPH - 免费报告）股票中的持股比例，第四季度持股下降了 71.5%，根据其最近向证券交易委员会提交的 13F 表格。该机构投资者在本季度出售了 385,349 股后，持有 153,571 股该公司的股票。截至最近报告期末，摩根大通持有的 Amphastar Pharmaceuticals 的股份约占 0.32%，价值 5,702,000 美元。</p>
</div><ul>
<li>Top 2 Small Cap Healthcare Stocks to Buy Before Rate Cuts</li>
</ul>
<div class="lb-trans"><ul>
<li>在降息前值得购买的前两只小型医疗股</li>
</ul>
</div><p>Several other institutional investors and hedge funds also recently added to or reduced their stakes in AMPH. Pacer Advisors Inc. lifted its stake in Amphastar Pharmaceuticals by 51,977.4% in the 4th quarter. Pacer Advisors Inc. now owns 1,350,368 shares of the company's stock worth $50,139,000 after purchasing an additional 1,347,775 shares in the last quarter. Boston Trust Walden Corp grew its stake in shares of Amphastar Pharmaceuticals by 81.4% during the fourth quarter. Boston Trust Walden Corp now owns 978,920 shares of the company's stock valued at $36,347,000 after buying an additional 439,281 shares during the last quarter. Boston Partners bought a new stake in shares of Amphastar Pharmaceuticals during the fourth quarter valued at approximately $15,778,000. Wealthfront Advisers LLC purchased a new position in Amphastar Pharmaceuticals during the 4th quarter worth $9,268,000. Finally, Raymond James Financial Inc. bought a new stake in Amphastar Pharmaceuticals during the 4th quarter valued at $3,450,000. Institutional investors own 65.09% of the company's stock.</p>
<div class="lb-trans"><p>其他几家机构投资者和对冲基金最近也增加或减少了对 AMPH 的持股。Pacer Advisors Inc.在第四季度将其在 Amphastar Pharmaceuticals 的持股比例提高了 51,977.4%。Pacer Advisors Inc.现在持有 1,350,368 股该公司的股票，价值 50,139,000 美元，此前在上个季度又购买了 1,347,775 股。Boston Trust Walden Corp 在第四季度将其在 Amphastar Pharmaceuticals 的持股比例提高了 81.4%。Boston Trust Walden Corp 现在持有 978,920 股该公司的股票，价值 36,347,000 美元，此前在上个季度又购买了 439,281 股。Boston Partners 在第四季度购买了价值约 15,778,000 美元的 Amphastar Pharmaceuticals 新股份。Wealthfront Advisers LLC 在第四季度购买了价值 9,268,000 美元的 Amphastar Pharmaceuticals 新股份。最后，Raymond James Financial Inc.在第四季度购买了价值 3,450,000 美元的 Amphastar Pharmaceuticals 新股份。机构投资者持有该公司 65.09% 的股票。</p>
</div><h2>Insider Buying and Selling at Amphastar Pharmaceuticals</h2>
<div class="lb-trans"><h2>Amphastar Pharmaceuticals 的内部买卖</h2>
</div><p>In related news, CFO William J. Peters sold 4,231 shares of Amphastar Pharmaceuticals stock in a transaction on Tuesday, March 4th. The stock was sold at an average price of $27.54, for a total value of $116,521.74. Following the completion of the transaction, the chief financial officer now directly owns 97,363 shares in the company, valued at approximately $2,681,377.02. This trade represents a 4.16 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 27.10% of the stock is owned by insiders.</p>
<div class="lb-trans"><p>在相关消息中，首席财务官 William J. Peters 于 3 月 4 日星期二出售了 4,231 股 Amphastar Pharmaceuticals 的股票。该股票以 27.54 美元的平均价格出售，总价值为 116,521.74 美元。交易完成后，首席财务官现在直接持有 97,363 股该公司的股票，价值约为 2,681,377.02 美元。这笔交易代表了他们持有股票的比例减少了 4.16%。该交易已在向 SEC 提交的文件中披露，相关文件可通过此链接访问。27.10% 的股票由内部人士持有。</p>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析师设定新目标价</h2>
</div><ul>
<li>Promising Small Biotech Amphastar Sees Actionable Pullback</li>
</ul>
<div class="lb-trans"><ul>
<li>有前景的小型生物技术公司 Amphastar 经历了可操作的回调</li>
</ul>
</div><p>Several research analysts recently weighed in on AMPH shares. Piper Sandler reduced their target price on Amphastar Pharmaceuticals from $36.00 to $32.00 and set a &#34;neutral&#34; rating on the stock in a research report on Friday, March 21st. Needham &amp; Company LLC restated a &#34;hold&#34; rating on shares of Amphastar Pharmaceuticals in a research note on Thursday, April 10th.</p>
<div class="lb-trans"><p>几位研究分析师最近对 AMPH 股票发表了看法。Piper Sandler 将 Amphastar Pharmaceuticals 的目标价从 36.00 美元下调至 32.00 美元，并在 3 月 21 日的研究报告中对该股票给予了 “中性” 评级。Needham &amp; Company LLC 在 4 月 10 日的研究报告中重申了对 Amphastar Pharmaceuticals 股票的 “持有” 评级。</p>
</div><p><strong>Read Our Latest Stock Analysis on AMPH</strong></p>
<div class="lb-trans"><p><strong>阅读我们最新的 AMPH 股票分析</strong></p>
</div><h2>Amphastar Pharmaceuticals Stock Up 1.6 %</h2>
<div class="lb-trans"><h2>Amphastar Pharmaceuticals 股票上涨 1.6%</h2>
</div><p>Shares of AMPH opened at $23.35 on Friday. The stock's 50-day moving average price is $27.78 and its 200-day moving average price is $37.36. Amphastar Pharmaceuticals, Inc. has a 52 week low of $22.64 and a 52 week high of $53.96. The company has a market capitalization of $1.11 billion, a price-to-earnings ratio of 7.78, a PEG ratio of 2.19 and a beta of 0.79. The company has a quick ratio of 2.61, a current ratio of 3.43 and a debt-to-equity ratio of 0.82.</p>
<div class="lb-trans"><p>AMPH 的股票在周五开盘价为 23.35 美元。该股票的 50 日移动平均价格为 27.78 美元，200 日移动平均价格为 37.36 美元。Amphastar Pharmaceuticals, Inc.的 52 周最低价为 22.64 美元，最高价为 53.96 美元。该公司的市值为 11.1 亿美元，市盈率为 7.78，PEG 比率为 2.19，贝塔值为 0.79。该公司的速动比率为 2.61，流动比率为 3.43，债务与股本比率为 0.82。</p>
</div><h2>Amphastar Pharmaceuticals Company Profile</h2>
<div class="lb-trans"><h2>Amphastar Pharmaceuticals 公司简介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.</p>
<div class="lb-trans"><p>Amphastar Pharmaceuticals, Inc.是一家生物制药公司，在美国、中国和法国开发、生产、营销和销售仿制药和专有的注射、吸入和鼻用产品。它提供 BAQSIMI，一种用于治疗严重低血糖的鼻用喷雾剂；Primatene Mist，一种用于暂时缓解间歇性哮喘轻微症状的非处方肾上腺素吸入产品；Enoxaparin，用于预防和治疗深静脉血栓；REXTOVY 和 Naloxone 用于阿片类药物过量；用于紧急情况的胰高血糖素注射套件；以及 Cortrosyn，用作筛查肾上腺皮质功能不全患者的诊断剂。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精选文章</h2>
</div><ul>
<li>Five stocks we like better than Amphastar Pharmaceuticals</li>
<li>What Are Dividends? Buy the Best Dividend Stocks</li>
<li>3 Mid-Cap to Mega-Cap Stocks Have Announced Significant Buybacks</li>
<li>What is the Dogs of the Dow Strategy? Overview and Examples</li>
<li>These 3 Stocks Have Huge Last 12 Months Shareholder Yields</li>
<li>Growth Stocks: What They Are, Examples and How to Invest</li>
<li>Prominent Hedge Fund Acquires Huge Stake in HPE: Is It a Buy Now?</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票超过 Amphastar Pharmaceuticals</li>
<li>什么是股息？购买最佳股息股票</li>
<li>3 只中型到大型股票宣布了重大回购</li>
<li>什么是道琼斯狗策略？概述和示例</li>
<li>这 3 只股票在过去 12 个月中为股东带来了巨大的收益</li>
<li>成长股：它们是什么，示例及如何投资</li>
<li>知名对冲基金收购 HPE 的巨大股份：现在值得购买吗？</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding AMPH?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH - Free Report).</p>
<div class="lb-trans"><p><strong>想看看其他对冲基金持有的 AMPH 吗？</strong> 访问 HoldingsChannel.com 获取 Amphastar Pharmaceuticals, Inc.（NASDAQ:AMPH - 免费报告）的最新 13F 文件和内部交易。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QU1QSA" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=AMPH"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对本故事有任何问题或意见，请发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Amphastar Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Amphastar Pharmaceuticals 吗？</h2>
</div><p>Before you consider Amphastar Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑投资 Amphastar Pharmaceuticals 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Amphastar Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐，现在就购买，以便在更广泛的市场注意到之前……而 Amphastar Pharmaceuticals 并不在名单上。</p>
</div><p>While Amphastar Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Amphastar Pharmaceuticals 目前在分析师中获得 “持有” 评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

摩根大通出售了 385,349 股 Amphastar 制药公司（NASDAQ:AMPH）的股份